S J Harland

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Chemotherapy for hormone-resistant prostate cancer: Where are we today?
    Tomas Buchler
    Department of Oncology, University College London Hospital, London, United Kingdom
    Indian J Urol 23:55-60. 2007
  2. doi request reprint Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
    Stephen Harland
    UCL Cancer Institute, London, UK Electronic address
    Eur J Cancer 49:3648-57. 2013
  3. ncbi request reprint A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder
    S J Harland
    Institute of Urology and Department of Oncology, University College London, London, UK
    J Urol 178:807-13; discussion 813. 2007
  4. pmc Inheritance and testicular cancer
    P W Nicholson
    Department of Oncology, University College London Medical School, UK
    Br J Cancer 71:421-6. 1995
  5. pmc International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial
    Gareth Griffiths
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Clin Oncol 29:2171-7. 2011
  6. pmc Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
    M von Schlippe
    Department of Oncology, University College, London, WIN 8AA, UK
    Br J Cancer 85:823-6. 2001
  7. ncbi request reprint A second look at the pT1 G3 bladder tumour
    S J Harland
    Department of Oncology, Institute of Urology, University College London, UK
    Clin Oncol (R Coll Radiol) 17:498-502. 2005
  8. pmc Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
    A J Birtle
    The Meyerstein Institute of Oncology, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Br J Cancer 91:1472-6. 2004
  9. pmc Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
    D P Dearnaley
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:2107-13. 2005

Detail Information

Publications9

  1. pmc Chemotherapy for hormone-resistant prostate cancer: Where are we today?
    Tomas Buchler
    Department of Oncology, University College London Hospital, London, United Kingdom
    Indian J Urol 23:55-60. 2007
    ..Results of a recent trial suggest that the survival benefit may have been underestimated as a result of crossover from the less active to the active arm...
  2. doi request reprint Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
    Stephen Harland
    UCL Cancer Institute, London, UK Electronic address
    Eur J Cancer 49:3648-57. 2013
    ..Here we report on the impact of abiraterone therapy on the health-related quality of life (HRQoL) observed during this trial, assessed using the validated Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire...
  3. ncbi request reprint A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder
    S J Harland
    Institute of Urology and Department of Oncology, University College London, London, UK
    J Urol 178:807-13; discussion 813. 2007
    ....
  4. pmc Inheritance and testicular cancer
    P W Nicholson
    Department of Oncology, University College London Medical School, UK
    Br J Cancer 71:421-6. 1995
    ..One-third of all testis cancer patients are genetically predisposed to the disease. 4. The 2.2% risk to brothers of cases as reported elsewhere can be accounted for by the homozygous (recessive) inheritance of a single predisposing gene...
  5. pmc International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial
    Gareth Griffiths
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Clin Oncol 29:2171-7. 2011
    ..Nine hundred seventy-six patients were recruited between 1989 and 1995, and median follow-up is now 8.0 years...
  6. pmc Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
    M von Schlippe
    Department of Oncology, University College, London, WIN 8AA, UK
    Br J Cancer 85:823-6. 2001
    ..009) and significant improvement between 3 and 12 months after chemotherapy (P = 0.038). Sural nerve sensory action potentials and conduction velocities were unhelpful...
  7. ncbi request reprint A second look at the pT1 G3 bladder tumour
    S J Harland
    Department of Oncology, Institute of Urology, University College London, UK
    Clin Oncol (R Coll Radiol) 17:498-502. 2005
    ..Identification of patients at extra high risk of progression is desirable. Tumour size, the co-existence of carcinoma in situ and early tumour recurrence may be prognostic indicators, but the data are at present insufficient...
  8. pmc Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
    A J Birtle
    The Meyerstein Institute of Oncology, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK
    Br J Cancer 91:1472-6. 2004
    ..While similar responses have been documented for systemic cytotoxic-steroid combinations, the responses in this study are likely to reflect the activity of cytotoxic drugs alone...
  9. pmc Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
    D P Dearnaley
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:2107-13. 2005
    ..There are no clearcut advantages to 2 x BOP over 2 x BEP, except for patients who wish to maximise the chance of avoiding significant alopecia...